| 注册
首页|期刊导航|山东医药|33例血管免疫母细胞性T细胞淋巴瘤临床特征及预后分析

33例血管免疫母细胞性T细胞淋巴瘤临床特征及预后分析

孙慧 薛恺

山东医药Issue(19):11-13,3.
山东医药Issue(19):11-13,3.DOI:10.3969/j.issn.1002-266X.2015.19.004

33例血管免疫母细胞性T细胞淋巴瘤临床特征及预后分析

Clinical features and prognosis of 33 patients with angioimmunoblastic T-cell lymphoma

孙慧 1薛恺1

作者信息

  • 1. 复旦大学附属肿瘤医院,复旦大学上海医学院,上海200032
  • 折叠

摘要

Abstract

Objective To analyze the clinical characteristics and prognosis of patients with angioimmunoblastic T-cell lymphoma ( AITL) .Methods A retrospective analysis of 33 patients with AITL was performed in terms of basic clinical fea-tures, the therapeutic effect and prognostic factors.Results The median age of 33 patients was 61 years old, and 84.8%of them were male, 3 patients presented with poor performance status (ECOG score≥2), 27 cases had advanced stage (stageⅢ/Ⅳaccording to Ann Arbor classification), and 7 cases had elevated lactate dehydrogenase (LDH).Extranodal involve-ments included liver involvement (9.1%), spleen involvement (18.2%) and bone marrow involvement (9.1%).Fourteen patients presented with B symptom.Twenty four patients received CHOP regimen ( cyclophosphamide, doxorubicin, vincris-tine and prednisolone) as first-line chemotherapy.The 2-year overall survival ( OS) rate was 81.3% (95%CI: 0.734-0.892).The 2-year event-free survival (EFS) rate was 49.7%(95%CI:0.402-0.592).The elevated LDH, elevated white blood cell count and B symptom could affect 2-year OS rate (all P<0.05).ECOG score≥2, B symptom, skin rashes and a-nemia could affect 2-year EFS rate (all P<0.05).No statistical difference was found in 2-year OS rate between patients treated with non-CHOP and those with CHOP regimen.Multivariate analysis showed that ECOG score≥2 (P=0.023) was an independent adverse factor for worse EFS.B symptom (P=0.024) and the increased LDH level (P=0.034) were inde-pendent adverse factors for worse OS.Conclusions AITL usually occurs in elder men and presents with B symptom, skin ra-shes, eosinophilia, effusion and extranodal involvement.On onset of AITL, those with increased LDH and B symptom have a poor prognosis.Non-CHOP regimen in first-line chemotherapy is not superior to CHOP regimen.

关键词

淋巴瘤/血管免疫母细胞性T细胞淋巴瘤/ECOG评分/B症状

Key words

lymphoma/angioimmunoblastic T-cell lymphoma/ECOG score/B symptom

分类

医药卫生

引用本文复制引用

孙慧,薛恺..33例血管免疫母细胞性T细胞淋巴瘤临床特征及预后分析[J].山东医药,2015,(19):11-13,3.

基金项目

国家自然科学基金资助项目(81400161)。 ()

山东医药

OA北大核心CSTPCD

1002-266X

访问量0
|
下载量0
段落导航相关论文